Cranial cavity

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
CD33, Cancer, Gene expression, Cell, Cranial cavity, Myelodysplastic syndrome, DRI, EHA, Survival, Temozolomide, Research and development, Canadian Aviation Regulations, GBM, AML, Leukemia, IND, ASCO, CD123, Patient, Gene, CML, Society, Acute myeloid leukemia, AACR, Annual general meeting, MDS, Acute leukemia, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results for the first quarter ended March 31, 2024 and recent corporate highlights.
  • “We continued to make significant progress advancing our gamma-delta T cell programs in the first quarter of 2024,” said William Ho, CEO and co-founder of IN8bio.
  • INB-100: Report updated interim results from the ongoing Phase 1 investigator-sponsored trial at the 2024 EHA Annual Meeting, held June 13-16 in Madrid, Spain.
  • INB-200: Report interim Phase 1 long-term follow up results in GBM at multiple medical meetings in 2024 including at the 2024 ASCO Annual Meeting.

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Giovedì, Marzo 14, 2024
MGMT, Research, Survival, ASH, CD33, Environment, Patient, GBM, Neoplasm, Temozolomide, D&O, IND, AACR, Glioblastoma, Exposition, Research and development, Society, CD123, PFS, Cell, DRI, Cranial cavity, Pharmaceutical industry

(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
  • “IN8bio entered 2024 with significant momentum behind the company,” said William Ho, CEO and co-founder of IN8bio.
  • “Despite the difficult environment in 2023, the IN8bio team executed operationally and successfully advanced our programs.
  • Cash position: As of December 31, 2023, the Company had cash of $21.3 million, compared to $18.2 million as of December 31, 2022.

RapidAI to Enter ISC 2024 Showcasing Extensive Research and Unparalleled Industry Leadership

Retrieved on: 
Martedì, Febbraio 6, 2024
Science, Cardiology, Software, Research, Health, Artificial Intelligence, Health Technology, Technology, Conference, ISC, Critical care, American Heart, Intracranial hemorrhage, Cranial cavity, Ischemia, Hyatt Regency Phoenix, Patient, Multimodality, Implementation, Stroke, Artificial intelligence, Pharmaceutical industry

Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care.

Key Points: 
  • Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care.
  • “Our commitment to research and finding new, improved ways to enhance patient outcomes is a core pillar for us,” said Dr. David Stoffel, chief business officer of RapidAI.
  • February 7, 6:25 - 6:30 PM MST at Poster Hall, Halls 5-6
    Late-Breaking Science Oral Abstracts IV: Subgroup Analyses From the TIMELESS Trial, Gregory Albers, M.D.
  • Poster Presentation: Acute Ischemic Stroke Patients After Implementation of the RapidAI Platform in a Comprehensive Stroke Center in Santiago, Chile, Pablo Lavados, M.D., presented by Greg Albers, M.D.

Global Traumatic Brain Injuries Assessment Market Expected to Garner $18,373.6 Million by 2031, Growing at 7.0% CAGR from 2022-2031 [250-Pages] | Details by Research Dive

Retrieved on: 
Martedì, Gennaio 17, 2023
Accident, Blunt trauma, Hospital, Falls, Brain, Injury, Research, Brain damage, CT, Partial pressure, Completeness, Midsayap Diagnostic Center and Hospital, Growth, Patient, Intracranial pressure monitoring, Coronavirus, Partial, Traumatic brain injury, MRI, Cranial cavity, Others, Meat, Medical imaging, Medical device, Oxygen, Electronics

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Traumatic Brain Injuries Assessment Market, by End-user (Hospital, Diagnostics Center, and Others) and Diagnostic Type (CT-Scan, MRI, Electronics, Intracranial Pressure Monitoring, Partial Pressure of Oxygen in Brain Tissue (pBrO2), and Others) Global Opportunity Analysis and Industry Forecast, 2022-2031".

Key Points: 
  • The traumatic brain injuries assessment market is expected to grow by 2031 due to increasing cases of brain injuries.
  • This global increase is expected to immensely help the traumatic brain injuries assessment market grow in the forecast years.
  • Restraints: Low government funding in traumatic brain injury treatment, however, may dampen the growth rate of the traumatic brain injuries assessment market.
  • By regional analysis, the traumatic brain injuries assessment market in North America region is expected to be the most dominant by 2031.

Global Patient Monitoring Devices Market Report 2022: Increasing Demand for Patient Monitoring Devices in Non-Hospital Settings to Drive Future Growth - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Agosto 19, 2022
Medical Devices, Health, Biosensor, Spirometer, Multi, Fetal monitoring, Digital, Value, Cranial cavity, Insulation monitoring device, Business Growth Fund, Intracranial pressure monitoring, Research report, Decision-making, CAGR, Market share analysis, Growth, Use, Acquisition, Analog, Hospital, Health care, Fetus, Strategic management, Temperature, Customer support, Ambulatory Surgery Center Association, USD, Medical device, Retail, Disposable product

This research report categorizes the Patient Monitoring Devices to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Patient Monitoring Devices to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the market was studied across Blood Glucose Monitoring Systems, Cardiac Monitoring Devices, Fetal & Neonatal Monitoring Devices, Hemodynamic/Pressure Monitoring Devices, Multi-parameter Monitoring Devices, Neuromonitoring Devices, Respiratory Monitoring Devices, Temperature Monitoring Devices, and Weight Monitoring Devices.
  • The Fetal & Neonatal Monitoring Devices is further studied across Fetal Monitoring Devices and Neonatal Monitoring Devices.
  • The Multi-parameter Monitoring Devices is further studied across High-acuity Monitoring Devices, Low-acuity Monitoring Devices, and Mid-acuity Monitoring Devices.
  • The Temperature Monitoring Devices is further studied across Handheld Temperature Monitoring Devices, Invasive Temperature Monitoring Devices, Smart Temperature Monitoring Devices, Table-top Temperature Monitoring Devices, and Wearable Continuous Monitoring Devices.

Global Intracranial Hemorrhage Devices Market to 2027 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Luglio 7, 2022
Medical Devices, Health, Hospitals, Surgery, Neurology, Health Technology, Death, Stroke, Patient, USD, Competitive landscape, Brain, COVID-19, Population, Lists of diseases, Growth, Cranial cavity, Intracranial hemorrhage, Disease, Prevalence, ICH, Statistics, Risk, Intracerebral hemorrhage, Atherosclerosis, CAGR, Disability, Globe, Pharmaceutical industry

The "Intracranial Hemorrhage Devices- Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intracranial Hemorrhage Devices- Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.
  • Intracranial Hemorrhage (ICH) Devices Market Dynamics:
    The Intracranial Hemorrhage (ICH) Devices market is witnessing a growth in product demand owing to various reasons.
  • Hence, the growth of the Intracranial hemorrhage (ICH) Devices Market is expected to rise during the forecast period from 2022 to 2027.
  • However, the risk involved with Intracranial Hemorrhage (ICH) Devices and the high cost of equipment and surgeries may be certain limiting factors of the Intracranial Hemorrhage (ICH) Devices market growth.